Yahoo Web Search

Search results

1. • 

     Tumor mutations may not predict response to immuno | Newswise

     Newswise· 1 day ago

     May 22, 2024 – The number of mutations in the DNA of cancerous tumors may not be an indicator of how...

2. • 

     End-of-life systemic treatment for patients with advanced cancers does not improve survival, finds...

     Medical Xpress· 1 week ago

     Patients with very advanced solid tumors saw no significant improvement in overall survival after...

3. • Great Lakes Advisors LLC Has $1.11 Million Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

     ETF DAILY NEWS· 1 day ago

     Great Lakes Advisors LLC trimmed its holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 50.8% during the fourth quarter, according to its most recent 13F filing with the ...

4. • Principal Financial Group Inc. Trims Holdings in Exelixis, Inc. (NASDAQ:EXEL)

     ETF DAILY NEWS· 4 days ago

     Principal Financial Group Inc. lowered its position in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 2.9% during the 4th quarter, according to the company in its most recent disclosure ...

5. • Exelixis, Inc. (NASDAQ:EXEL) Shares Bought by BNP Paribas Financial Markets

     ETF DAILY NEWS· 6 days ago

     BNP Paribas Financial Markets increased its stake in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 88.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities ...

6. • Natixis Advisors L.P. Cuts Holdings in Exelixis, Inc. (NASDAQ:EXEL)

     ETF DAILY NEWS· 4 days ago

     Natixis Advisors L.P. lessened its position in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 3.1% in the fourth quarter, according to the company in its most recent Form 13F filing ...

7. • Exelixis (NASDAQ:EXEL) Now Covered by Stephens

     ETF DAILY NEWS· 5 days ago

     Stephens started coverage on shares of Exelixis (NASDAQ:EXEL – Free Report) in a report issued on Tuesday morning, MarketBeat Ratings reports. The firm issued an equal weight rating and a $23.00 ...

8. • Swiss National Bank Has $3.57 Million Stock Holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

     ETF DAILY NEWS· 2 days ago

     Swiss National Bank lowered its stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 10.2% in the fourth quarter, according to its most recent 13F filing with the ...